Browsing Tag
NASDAQ: PRAX
1 post
Could essential tremor finally be entering a new treatment era after Praxis’ Phase 3 results?
Praxis Precision Medicines’ Phase 3 results could reshape essential tremor treatment and re-rate the neurology market. Read what this means for investors.